The effect of a 1-deoxynojirimycin derivative on post-prandial blood glucose and insulin levels in healthy black and white volunteers.
BAY m1099 (a 1-deoxynojirimycin derivative) is a glucose analogue which is an alpha-glucosidase inhibitor. Its effects on post-prandial blood glucose and insulin levels was compared with a placebo in 12 healthy male volunteers (6 Blacks and 6 Whites). It produced a similar, significant depression of post-prandial blood glucose and insulin levels when the groups were assessed separately and when the data were pooled. Although blood insulin levels in Whites were higher than in Blacks, as previously reported, the difference was not statistically significant and did not appear to influence the response to the drug. BAY 1099 produced no objective or subjective untoward effects and appears to warrant further investigation as an adjuvant to dietary control of diabetes mellitus.
Joubert
P H
PH
Venter
C P
CP
Joubert
H F
HF
Hillebrand
I
I
D017485:1-Deoxynojirimycin; D000328:Adult; D044383:Black People; D001786:Blood Glucose / Q000378:metabolism*; D004435:Eating; D005944:Glucosamine / Q000031:analogs & derivatives / Q000494:pharmacology; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000097:blood*; D044469:Racial Groups; D044465:White People
D001786:Blood Glucose; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D017485:1-Deoxynojirimycin; D005959:Glucosidases; D005944:Glucosamine